FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
Go back to FDA Approves Expanded Age Indication for GARDASIL® 9 in Males| Merck & Co. (NYSE: MRK) | Delayed: 148.36 -1.16 (0.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.52 | 52 Week High | $65.46 | |||
| Open | $148.82 | 52 Week Low | $47.97 | |||
| Day High | $150.27 | P/E | 100.93 | |||
| Day Low | $147.10 | EPS | $1.47 | |||
| Volume | 9,075,658 | |||||



